male hypogonadism
Diagnose only when consistent symptoms/signs accompany two separate fasting early-morning (08:00–10:00) low total testosterone levels (typically <9.2 nmol/L on CDC-harmonised assays); measure free testosterone (equilibrium dialysis or calculated from total T, SHBG, and albumin) if SHBG is altered (e.g., obesity, diabetes, ageing, liver/thyroid disease) or total T is borderline. Split primary vs secondary with LH and FSH, and obtain a pituitary MRI in secondary hypogonadism when total T <5.2 nmol/L, prolactin is elevated, or mass-effect/panhypopituitarism features exist. Never give exogenous testosterone to men seeking near-term fertility (suppresses spermatogenesis).
- Pituitary tumour: secondary hypogonadism with total T <5.2 nmol/L, elevated prolactin, other pituitary deficits, or headache/visual field loss requires a dedicated pituitary MRI (see pituitary disorders).
- Exogenous testosterone and fertility: testosterone suppresses LH/FSH and causes azoospermia — contraindicated in men planning fertility in the near term (use gonadotropins/specialist referral instead).
- Haemochromatosis: always consider iron studies (ferritin, transferrin saturation) in unexplained secondary hypogonadism.
step 1 — confirm testosterone deficiency (ES 2018)
- Do not screen asymptomatic men in the general population; test men with specific symptoms/signs (reduced libido, erectile dysfunction, loss of spontaneous erections, gynaecomastia, small testes <6 mL, hot flushes, low-trauma fracture/osteoporosis, unexplained anaemia) or high-risk conditions (sellar mass, HIV weight loss, chronic opioid or glucocorticoid therapy)
- Diagnostic rule:
- Draw fasting morning (08:00–10:00) total testosterone when the patient is not acutely ill
- Repeat on a separate morning to confirm (up to 30% of men with one low reading normalise on repeat)
- CDC-harmonised lower limit in healthy non-obese young men = 9.2 nmol/L (use local validated lab reference range)
- When to check free testosterone (equilibrium dialysis or Vermeulen calculation using total T + SHBG + albumin; avoid direct immunoassay free T):
- Borderline total T around the lower limit of normal
- Conditions lowering SHBG (falsely low total T despite normal free T): obesity, type 2 diabetes, insulin resistance, nephrotic syndrome, hypothyroidism, glucocorticoids/androgens
- Conditions raising SHBG (falsely normal total T despite low free T): ageing, cirrhosis/hepatitis, hyperthyroidism, HIV, anticonvulsants
step 2 — localise primary vs secondary hypogonadism
Measure LH and FSH after confirming low testosterone:
| type | LH & FSH | key causes | targeted workup |
|---|---|---|---|
| primary (hypergonadotropic) | high | Klinefelter syndrome (47,XXY), cryptorchidism, mumps orchitis, testicular trauma/torsion, chemotherapy/pelvic radiation, myotonic dystrophy | karyotype if small firm testes (<6 mL), eunuchoid proportions (arm span > height + 5 cm), gynaecomastia, or azoospermia |
| secondary (hypogonadotropic) | low or inappropriately normal | pituitary adenoma / hypopituitarism, hyperprolactinaemia, haemochromatosis, opioids, anabolic steroids, glucocorticoids, severe obesity / T2DM (functional), Kallmann syndrome (anosmia) | prolactin, iron studies (ferritin, TSAT), anterior pituitary screen (TSH/FT4, AM cortisol); pituitary MRI if total T <5.2 nmol/L, ↑ PRL, panhypopituitarism, or visual/headache symptoms |
- Klinefelter syndrome (47,XXY): commonest genetic cause of primary hypogonadism; associated with small firm testes, gynaecomastia, infertility, low bone density, type 2 diabetes, and increased risk of male breast cancer, mediastinal germ-cell tumours, and autoimmune disease
testosterone therapy and monitoring (ES 2018)
contraindications (do not start testosterone)
- Desire for near-term fertility
- Breast cancer or prostate cancer
- Palpable prostate nodule/induration or PSA >4 µg/L (or >3 µg/L in high-risk men — Black men or first-degree relative with prostate cancer) without urological clearance
- Baseline haematocrit >48% (>50% at high altitude)
- Untreated severe OSA, severe LUTS (IPSS >19), uncontrolled heart failure, MI or stroke within the past 6 months, or thrombophilia
- Older men (≥65 y): do not prescribe routinely for age-related decline; discuss risks/benefits individually only if unequivocal symptomatic deficiency
- type 2 diabetes: do not prescribe testosterone solely to improve glycaemic control
formulations and monitoring
- Options: transdermal gel/patch (steady levels; counsel on skin-to-skin transfer to women/children) or IM esters (testosterone enanthate/cypionate q1–2 wk; higher risk of erythrocytosis)
- Target: mid-normal serum testosterone (timing depends on formulation — e.g., midway between IM injections, or any morning on transdermal gel)
- Monitoring schedule: check symptoms, testosterone, and haematocrit at 3–6 months, then annually; discuss age-appropriate PSA/DRE screening (men 55–69 y, or 40–69 y if high-risk, with >10-y life expectancy) at 3–12 months then per standard screening; assess BMD at 1–2 years if osteoporotic
- Action thresholds:
- Haematocrit >54%: stop testosterone until haematocrit normalises, evaluate for hypoxia/OSA, then restart at a lower dose (or switch IM → transdermal)
- Urology referral in the first 12 months if confirmed PSA rise >1.4 µg/L above baseline, confirmed PSA >4.0 µg/L, or abnormal DRE
- Gynaecomastia (palpable glandular subareolar tissue, distinct from pseudogynaecomastia/fat): exclude breast cancer (hard, eccentric, fixed, nipple discharge), review drugs (spironolactone, finasteride, cimetidine, ketoconazole, antipsychotics, opioids, cannabis/anabolic steroids), and check LH, FSH, testosterone, oestradiol, β-hCG (testicular germ-cell tumour), TSH, and liver/renal function
Prepared 2026-11-19. Not yet verified — check every number against the sources.